JUN and neoplasm: Another member of the MAPK-pathway, the so-called proto-oncogene c-Jun, is also central to cancer-altered signalling: an upregulated c-Jun was described for variable tumor cells, specifically in brain tumors, contributing to its malignancy (Blau et al., 2012).